前列腺癌与生物标志物在筛查和诊断中不断演变的作用
Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis.
作者信息
Rodriguez Joseph F, Eggener Scott E
机构信息
Section of Urology, University of Chicago, The University of Chicago Medicine, 5841 South Maryland Avenue, MC 6038, Chicago, IL 60637, USA.
Section of Urology, University of Chicago, The University of Chicago Medicine, 5841 South Maryland Avenue, MC 6038, Chicago, IL 60637, USA.
出版信息
Radiol Clin North Am. 2018 Mar;56(2):187-196. doi: 10.1016/j.rcl.2017.10.002. Epub 2017 Nov 26.
The diagnosis and management of prostate cancer have substantially changed over the last 3 decades. Serum prostate-specific antigen (PSA) was adopted for screening in the 1990s after it was found to be a sensitive indicator of disease. Because of a lack of specificity for significant disease, indiscriminate PSA testing led to overdiagnosis and overtreatment. Several biomarkers have been developed that are superior to PSA in stratifying a man's risk for harboring potentially lethal prostate cancer.
在过去30年里，前列腺癌的诊断和治疗发生了重大变化。血清前列腺特异性抗原（PSA）在20世纪90年代被发现是一种疾病敏感指标后，被用于筛查。由于对重大疾病缺乏特异性，不加区分的PSA检测导致了过度诊断和过度治疗。已经开发出了几种生物标志物，它们在评估男性患潜在致命性前列腺癌的风险方面优于PSA。
Zotero 插件